Clinical Trial News and Research

RSS

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.

10 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

10 Mar 2010

$Advances in back care and treatment options for slipped disc, spine surgery and vertebral fractures$

Advances in back care and treatment options for slipped disc, spine surgery and vertebral fractures

Approximately 21 million visits were made to physicians' offices due to back problems in 2006. While countless adults experience back pain and stiffness, many suffer from serious spine and back conditions -including injury, herniated discs and the deterioration of the vertebrae. Three new studies presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) detail advances in back care and treatment options for specific back and spine conditions.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Integrated public and investor relations healthcare and life sciences practice launched

Feintuch Communications, Inc. (www.feintuchcommunications.com) has created an integrated public and investor relations healthcare and life sciences practice, naming Jules Abraham as vice president of the firm and managing director of the new group.

10 Mar 2010

Alison Walker selected to receive ASH-AMFDP Award

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.

10 Mar 2010

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

10 Mar 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma Corp. today announced financial results for the second quarter ended January 31, 2010.

10 Mar 2010

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

Researchers at Cedars-Sinai Medical Center in Los Angeles, the University of California, San Diego School of Medicine, and UTHealth's Medical School will collaborate on the largest clinical trial of hypothermia (brain cooling) for stroke to date.

10 Mar 2010

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

OVA1™, the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc., the world's leading cancer diagnostics provider.

From Quest Diagnostics 10 Mar 2010

Side-Out Foundation sponsors new advanced breast cancer clinical trial

The Side-Out Foundation, which pairs volleyball enthusiasts with breast cancer researchers, is sponsoring a new clinical trial for up to 25 patients with advanced breast cancer.

10 Mar 2010

Scivanta Medical announces initial clinical trial results for SCMS

Scivanta Medical Corporation, today announced that the results of its initial clinical trial for the Scivanta Cardiac Monitoring System (SCMS) clearly indicate that the SCMS can accurately measure cardiac performance as expected by the company. This clinical trial was performed at Kaleida Health/Millard Fillmore Hospital in Buffalo, New York.

10 Mar 2010

Kendle implements new biostatistics infrastructure to enhance delivery of quality clinical trial data

Kendle, a leading, global full-service clinical research organization, today announced the implementation of a new biostatistics infrastructure that will significantly enhance the analysis and delivery of quality clinical trial data for customers.

10 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.

9 Mar 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Clinical Trial News and Research

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Advances in back care and treatment options for slipped disc, spine surgery and vertebral fractures

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Integrated public and investor relations healthcare and life sciences practice launched

Alison Walker selected to receive ASH-AMFDP Award

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

Side-Out Foundation sponsors new advanced breast cancer clinical trial

Scivanta Medical announces initial clinical trial results for SCMS

Kendle implements new biostatistics infrastructure to enhance delivery of quality clinical trial data

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Bypass surgery: New method of growing arteries could lead to non-invasive option for treatment

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery